Clinical trial
Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients…
NCT00054717 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00054717 |
|---|---|
| Title | Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST) |
| Official title | Randomized, Open-label, Comparative Safety and Efficacy Study of Tipranavir Boosted With Low-dose Ritonavir (TPV/RTV) Verses Genotypically-defined Protease Inhibitor/Ritonavir (PI/RTV) in Multiple Antiretroviral Drug-experienced Patients. |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Tipranavir, Ritonavir(r), Comparator Protease Inhibitor (CPI) |
| Enrollment | 630 |
| Start date | Jan 1, 2003 |
| Primary completion | Sep 1, 2008 |
| First posted | Feb 10, 2003 |
| Last update posted | Jul 2, 2014 |
| Countries | Australia, Canada, Puerto Rico, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: